Daiichi Sankyo confirmed an appeal by NTK regarding its acquisition of Fortis Healthcare. The defendant faces a massive Y203.3 billion damages claim despite winning the first-instance trial.
Daiichi Sankyo detailed the litigation timeline in a Sept 10, 2026 press release. The Tokyo District Court had previously dismissed all claims by Northern TK Venture Pte Ltd (NTK). However, NTK filed an appeal with the Tokyo High Court on Sept 24, just two weeks later. The dispute stems from Daiichi Sankyo enforcing a 2016 arbitration award against Fortis Healthcare in India. Indian courts had previously halted the bid due to alleged interference, prompting NTK's lawsuit.
NTK seeks Y203,318,078,400 in damages, alongside injunctions against share acquisition and demands to post specific statements on the company website. This amount is significant relative to Daiichi Sankyo's net income. The case highlights tensions between Japanese corporate governance and Indian regulatory environments. The outcome may set important precedents for overseas M&A risk management for Japanese firms.
Daiichi Sankyo maintains its position that the first-instance judgment was fair and will defend its stance. The company stated it is currently assessing specific impacts on consolidated results, making financial impact determination difficult at this time. While overseas M&A litigation risks are often minor, this case involves the entire value of the target. Investors should monitor quarterly notes for potential loss provisions.
Analyst take
The swift appeal suggests NTK will fiercely contest the case. Investors should focus on the timing of loss recognition and settlement possibilities. The reality of this massive claim demands rigorous risk management.
